DMK PHARMACEUTICALS Corp
DMKPQHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|---|
| Revenue | $4.8M | $2.2M | $16.5M | $22.1M | $15.1M | $13.1M |
| Operating income | −$25.1M | −$32.1M | −$36.3M | −$29.4M | −$39.5M | −$24.8M |
| Net income | −$26.5M | −$45.8M | −$49.4M | −$27.5M | −$39.0M | −$25.5M |
| Total assets | $10.9M | $38.3M | $30.9M | $47.8M | $58.4M | $51.4M |
| Total liabilities | $11.6M | $12.4M | $27.4M | $14.8M | $11.7M | $11.9M |
| Equity | −$808,068 | $25.9M | $6.0M | $33.0M | $46.7M | $39.5M |
| EPS (diluted) | $-0.18 | $-0.32 | — | — | — | — |
| Shares out. | 149.7M | 148.9M | 73.7M | 47.3M | 33.4M | 22.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- −526.9%
- Net margin
- −556.7%
- Return on equity
- 3276.7%
- Return on assets
- −242.2%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 106.0%
- Debt / equity
- —
- Book value / share
- $-0.01
- Revenue growth (YoY)
- 115.3%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- -107.59distress
- Accruals / assets
- −5.3%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Aug 14, 2023
- NT 10-Qmissed a reporting deadline ↗Nov 15, 2021
- NT 10-Qmissed a reporting deadline ↗Aug 16, 2021
- NT 10-Q/Amissed a reporting deadline ↗May 24, 2021
- NT 10-Qmissed a reporting deadline ↗May 17, 2021
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2021
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Oct 31, 2025 | 1,888 | 1.1 | 0.0% |
| Oct 15, 2025 | 1,888 | 1.0 | 0.0% |
| Sep 30, 2025 | 1,888 | 1.0 | 0.0% |
| Sep 15, 2025 | 1,888 | 1000.0 | 0.0% |
| Aug 29, 2025 | 1,888 | 1.0 | 0.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Director / officer changeJul 1, 2024
- Delisting / listing-standard noticeFeb 7, 2024
- Bankruptcy or receivership · Regulation FD disclosure · Other material eventFeb 5, 2024
- Shareholder voteJan 31, 2024
- Modified shareholder rights · Amended charter or bylawsJan 23, 2024
- Shareholder vote · Other material eventJan 3, 2024
- Regulation FD disclosureJan 3, 2024
- Terminated a material agreement · Other material eventDec 21, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-KCURRENT REPORTJul 1, 2024
- 25-NSEMar 21, 2024
- 8-KCURRENT REPORTFeb 7, 2024
- SC 13G/AAMENDMENT NO. 1 TO SCHEDULE 13GFeb 6, 2024
- 8-KCURRENT REPORTFeb 5, 2024
- 8-KCURRENT REPORTJan 31, 2024
- DEFA14AADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALSJan 23, 2024
- 8-KCURRENT REPORTJan 23, 2024
- DEFA14AADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALSJan 3, 2024
- 8-KCURRENT REPORTJan 3, 2024
- 8-KCURRENT REPORTJan 3, 2024
- 8-KCURRENT REPORTDec 21, 2023
- DEFA14AADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALSDec 4, 2023
- 8-KCURRENT REPORTDec 4, 2023
- 8-KCURRENT REPORTNov 28, 2023
Event-driven situations (3)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.